A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
ClinicalTrials.gov · NCT07518121 · Registry updated: 2026-11-20
- Condition / research focus
- Diabete Type 2
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Countries with listed sites
- Brazil
- Registry dates and results
- Start: 2026-06-01. Completion: 2026-10-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Efsubaglutide Alfa Injection (drug)
- Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- A2Z Clinical Centro Avançado de Pesquisa Clínica LTDA
Valinhos, São Paulo, Brazil
Site recruitment: Not reported